Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity

Vivani Medical, Inc.

NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.
Disclosed semaglutide as API in NPM-139, a once-yearly implant for chronic weight management.
Strategic shift to prioritize obesity implants; NPM-115 designed for twice-yearly dosing.
IND for NPM-119 (type 2 diabetes) on clinical hold; expects to submit CMC info to FDA in H1 2024.
Plans to submit IND for NPM-115 first-in-human obesity study later in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.